Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BD Diagnostics, a segment of Becton Dickinson and Company, has received CE mark for BD GeneOhm Cdiff molecular assay for the rapid diagnosis of patients with Clostridium difficile infection.
Subscribe to our email newsletter
BD Diagnostics’s GeneOhm Cdiff molecular assay is said to be the first Clostridium difficile infection (CDI) diagnostic test that offers sensitivity, simplicity and speed in one test procedure. BD has also submitted this assay to the FDA for clearance.
The BD GeneOhm Cdiff assay targets the toxin B gene, found in toxigenic Clostriduim difficile strains. This assay facilitates earlier appropriate treatment of patients suffering from CDI and earlier implementation of infection control interventions to prevent transmission of Clostridium difficile to other patients.
Jamie Condie, vice president and general manager of BD Diagnostics, said: “The introduction of the BD GeneOhm Cdiff assay demonstrates BD’s ongoing commitment to develop a broad range of products that can help prevent healthcare-associated infections.”